Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial

This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Todo, Tomoki, Ito, Hirotaka, Ino, Yasushi, Ohtsu, Hiroshi, Ota, Yasunori, Shibahara, Junji, Tanaka, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388376/
https://www.ncbi.nlm.nih.gov/pubmed/35864254
http://dx.doi.org/10.1038/s41591-022-01897-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388376/
https://www.ncbi.nlm.nih.gov/pubmed/35864254
http://dx.doi.org/10.1038/s41591-022-01897-x

Ejemplares similares